Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer

Yang, Fang; Tang, Jun; Zhao, Zihao; Zhao, Chunling; Xiang, Yuancai

doi:10.1186/s12958-021-00860-8

Cited by 21 publications

(18 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, inflammatory chemokines are also increasingly expressed in other tumor entities, such as lung carcinoma or lymphoma [ 52 , 53 ]. Therefore, next to detection of various glycoproteins, such as Ca-125 or HE4, there are innovative approaches, such as the detection of circulating tumor DNA, or extracellular vesicles in serum [ 54 , 55 ]. Moreover, in the future, a combination of different markers and/or different strategies might be the key for early detection of OvCa.…”

Section: Discussionmentioning

confidence: 99%

Nectin-4 as Blood-Based Biomarker Enables Detection of Early Ovarian Cancer Stages

Rogmans

Feuerborn

Treeck

et al. 2022

Cancers

View full text Add to dashboard Cite

Ovarian cancer is the third most common gynecological malignancy and has the highest mortality rate. Owing to unspecific symptoms, ovarian cancer is not detected until an advanced stage in about two-thirds of cases. Therefore, it is crucial to establish reliable biomarkers for the early stages to improve the patients’ prognosis. The aim of this study is to investigate whether the ADAM17 substrates Nectin-4, Heparin-binding EGF-like growth factor (HB-EGF) and Amphiregulin (AREG) could function as potential tumor markers for ovarian cancer. In this study a set of 231 sera consisting of 131 ovarian cancer patients and 100 healthy age-matched controls were assembled. Nectin-4, HB-EGF and AREG levels of preoperatively collected sera were determined by enzyme-linked immunosorbent assay (ELISA). Our analysis revealed that Nectin-4 and HB-EGF were significantly increased compared to the age-matched control group (p < 0.0001, p = 0.016). Strikingly, significantly higher Nectin-4 and HB-EGF levels were detected in early-stage FIGO I/II (p <0.001; p = 0.025) compared to healthy controls. Eighty-four percent (16/19) of patients with low Ca-125 levels showed increased Nectin-4 levels. Our study proposes Nectin-4 and HB-EGF as promising blood-based biomarkers for the detection of early stages of ovarian cancer patients that would not have been detected by Ca-125.

show abstract

Section: Discussionmentioning

confidence: 99%

Nectin-4 as Blood-Based Biomarker Enables Detection of Early Ovarian Cancer Stages

Rogmans

Feuerborn

Treeck

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Previous studies on the utility of ctDNA of ovarian cancer have mainly focused on early detection and screening (36,37), treatment response evaluation (38)(39)(40) and prognosis prediction (41). Higher levels of somatic mutations in ctDNA have been associated with decreased clinical benefit from treatment and shorter progression-free survival or overall survival (40,(42)(43)(44). By applying NGS or PCR, various types of genetic alterations in ctDNA and/or ovarian cancer tumor tissues have been found, including chromosomal rearrangements (45), chromosomal instability (46), DNA methylation (47,48), and gene mutation and amplification (43,49,50).…”

Section: Discussionmentioning

confidence: 99%

Mutation analysis of circulating tumor DNA and paired ascites and tumor tissues in ovarian cancer

Jie

Zhang

et al. 2022

Exp Ther Med

View full text Add to dashboard Cite

Circulating tumor DNA (ctDNA) is one conventional type of liquid biopsy that can be collected to dynamically monitor disease status. However, its potential clinical value and concordance with ascites samples or tumor biopsy needs to be evaluated further for patients with ovarian cancer. Therefore, the present study compared the mutation profiles among ctDNA, paired tumor tissue and ascites samples to explore their possible clinical value in ovarian cancer. Targeted next-generation sequencing was used to screen for mutations in 18 peripheral blood samples, six paired ascites samples and eight paired tumor tissues collected from patients with ovarian cancer. Functional analyses were performed using public databases. WebGestalt was used to perform Gene Ontology and pathway enrichment analyses. The cBioPortal for Cancer Genomics was used to assess therapeutic targets. Chilibot and Search Tool for the Retrieval of Interacting Genes/Proteins were used to obtain key genes and their functional interactions. Comparative analysis was performed among the three types of samples using Venn diagram. A total of 104 cancer-associated mutant genes in ctDNA samples, 95 genes in tumor tissues and 44 genes in ascites samples were found. A cluster covering 10 genes, namely NOTCH2, NOTCH3, lysine methyltransferase 2A, PTEN, androgen receptor, DNA-activated protein kinase catalytic subunit, hepatocyte nuclear factor 1 homeobox A, SRC, insulin receptor substrate 2 and SRY-box transcription factor 10, was obtained by Chilibot analysis. This gene panel may have the potential to monitor metastasis and identify therapeutic targets in ovarian cancer. Taken together, the present study focused on the mutant genes in ctDNA, ascites and tumor tissues, and suggested that the integrated information of different samples could be examined to comprehensively reflect the mutational landscape in ovarian cancer. However, procedures and protocols to interpret and utilize the integrated information obtained from various forms of liquid biopsies will require optimization prior to their use for future clinical applications.

show abstract

“…Although the increased amounts of this circulating DNA (unless it is proved circulating tumor DNA abbreviated as ctDNA) are not specific to cancer, it can be utilized as a screening method to indicate the need for further complete biomarker assessment. [32][33][34] Figure 2 represents the concept of free DNA concentration among cancer patients and normal healthy individuals.…”

Section: Gene Expressionmentioning

confidence: 99%

An Overview: Genetic Tumor Markers for Early Detection and Current Gene Therapy Strategies

Quraish¹,

Hirahata²,

Quraish³

et al. 2023

Cancer Inform

View full text Add to dashboard Cite

Genomic instability is considered a fundamental factor involved in any neoplastic disease. Consequently, the genetically unstable cells contribute to intratumoral genetic heterogeneity and phenotypic diversity of cancer. These genetic alterations can be detected by several diagnostic techniques of molecular biology and the detection of alteration in genomic integrity may serve as reliable genetic molecular markers for the early detection of cancer or cancer-related abnormal changes in the body cells. These genetic molecular markers can detect cancer earlier than any other method of cancer diagnosis, once a tumor is diagnosed, then replacement or therapeutic manipulation of these cancer-related abnormal genetic changes can be possible, which leads toward effective and target-specific cancer treatment and in many cases, personalized treatment of cancer could be performed without the adverse effects of chemotherapy and radiotherapy. In this review, we describe how these genetic molecular markers can be detected and the possible ways for the application of this gene diagnosis for gene therapy that can attack cancerous cells, directly or indirectly, which lead to overall improved management and quality of life for a cancer patient.

show abstract

Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer

Cited by 21 publications

References 101 publications

Nectin-4 as Blood-Based Biomarker Enables Detection of Early Ovarian Cancer Stages

Nectin-4 as Blood-Based Biomarker Enables Detection of Early Ovarian Cancer Stages

Mutation analysis of circulating tumor DNA and paired ascites and tumor tissues in ovarian cancer

An Overview: Genetic Tumor Markers for Early Detection and Current Gene Therapy Strategies

Contact Info

Product

Resources

About